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Abstract
Background: Mutations in isocitrate dehydrogenase 1 (IDH1) occur in various types of cancer and induce metabolic
alterations resulting from the neomorphic activity that causes production of D-2-hydroxyglutarate (D-2-HG) at the
expense of α-ketoglutarate (α-KG) and NADPH. To overcome metabolic stress induced by these alterations, IDH-
mutated (IDHmut) cancers utilize rescue mechanisms comprising pathways in which glutaminase and glutamate
dehydrogenase (GLUD) are involved. We hypothesized that inhibition of glutamate processing with the pleiotropic
GLUD-inhibitor epigallocatechin-3-gallate (EGCG) would not only hamper D-2-HG production, but also decrease
NAD(P)H and α-KG synthesis in IDHmut cancers, resulting in increased metabolic stress and increased sensitivity to
radiotherapy.
Methods: We performed 13C-tracing studies to show that HCT116 colorectal cancer cells with an IDH1R132H knock-in
allele depend more on glutaminolysis than on glycolysis for the production of D-2-HG. We treated HCT116 cells,
HCT116-IDH1R132H cells, and HT1080 cells (carrying an IDH1R132C mutation) with EGCG and evaluated D-2-HG
production, cell proliferation rates, and sensitivity to radiotherapy.
Results: Significant amounts of 13C from glutamate accumulate in D-2-HG in HCT116-IDH1wt/R132H but not in
HCT116-IDH1wt/wt. Preventing glutamate processing in HCT116-IDH1wt/R132H cells with EGCG resulted in reduction of
D-2-HG production. In addition, EGCG treatment decreased proliferation rates of IDH1mut cells and at high doses
sensitized cancer cells to ionizing radiation. Effects of EGCG in IDH-mutated cell lines were diminished by treatment
with the IDH1mut inhibitor AGI-5198.
Conclusions: This work shows that glutamate can be directly processed into D-2-HG and that reduction of
glutamatolysis may be an effective and promising new treatment option for IDHmut cancers.
Keywords: IDH mutations, Metabolism, EGCG, Radiotherapy, Glutamate
Background
Acquisition of hotspot mutations in IDH1 and IDH2 are
key events in the development of various types of
cancer. The mutations are found in 80–90% of gliomas
[1–3], in substantial percentages of acute myeloid
leukemia [4], chondrosarcoma [5], osteosarcoma [6], and
intrahepatic cholangiocarcinoma [7], and are sporadic-
ally found in other cancer types [8, 9].
IDH1 and IDH2 are NADP+-dependent homodimeric
enzymes that oxidize isocitrate (ICT) to α-ketoglutarate
(α-KG) in cytosol and mitochondria, respectively [10].
The NADPH produced by these reactions contributes to
the reductive potential of the cell [11]. Cancer-related
mutations in IDH1 and IDH2 are mostly heterozygous
and are always hotspot mutations involving arginine res-
idues R132 in IDH1 and R140 or R172 in IDH2. The
mutated subunits have acquired a neomorphic activity of
reducing α-KG to D-2-hydroxyglutarate (D-2-HG) while
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oxidizing NAPDH [12, 13]. Accumulation of D-2-HG
competitively inhibits α-KG-dependent enzymes, includ-
ing the ten-eleven translocation (TET) family of methyl-
cytosine dioxygenases, resulting in a CpG island
hypermethylator phenotype that is considered as a first
step in malignant transformation [14, 15]. Whereas IDH
mutations are involved in the initial steps of carcinogen-
esis, the metabolic and oxidative stress that comes with
the mutation may eventually slow down tumor progres-
sion, explaining the better survival of patients carrying
IDHmut gliomas [16, 17]. IDH mutations are however
not associated with prolonged survival in non-glioma
cancer patients, indicating tissue-specific effects that are
currently not understood [1, 3, 18].
Small molecule inhibitors of mutant IDH1 and IDH2
enzymes have been developed to prevent the production
of the alleged oncometabolite D-2-HG [19, 20]. How-
ever, blocking D-2-HG production also blocks NADPH
oxidation and consequently decreases oxidative stress,
desensitizing IDHmut cells for radiotherapy, chemother-
apy, and inhibitors of poly-ADP ribose polymerase
(PARP), an important enzyme involved in DNA double-
strand break (DSB) repair [21–24].
To improve the clinical outcomes of patients with
IDHmut cancers, it is essential to increase, rather than
decrease, metabolic stress. We previously showed that
clinical IDHmut gliomas have dramatically altered expres-
sion profiles of genes involved in metabolism as
compared to IDHwt gliomas. Based on these data, we
proposed a model in which IDHmut gliomas utilize the
neurotransmitter glutamate and lactate as fuels [25],
whereas IDHwt gliomas predominantly use glucose [26].
According to that model, the shortage of α-KG in IDHmut
gliomas is partially rescued by direct import of glutamate
that is converted to α-KG by the NAD+-/NADP+-depen-
dent enzymes glutamate dehydrogenase 1/2 (GLUD1/2).
In IDHmut non-gliomas, residing in environments with
low glutamate concentrations, this rescue pathway may
start with the import of glutamine that is first converted
to glutamate by mitochondrial glutaminase (GLS),
followed by GLUD1/2-mediated further processing to
α-KG. Multiple studies have shown that glutamine is a
major carbon donor for D-2-HG [27–29]. Alpha-KG can
then be shuttled into the TCA cycle or converted to
D-2-HG. We therefore hypothesized that inhibition of
glutamate processing in IDHmut cancer cells would not
only prevent D-2-HG production, but also NAD(P) H and
α-KG synthesis, thus increasing metabolic stress and
sensitizing IDHmut cancers to radiotherapy and chemo-
therapy [25, 30].
To test how different nutrients contribute to D-2-HG
production in non-glioma tumors, we here employed
HCT116 and HCT116-IDH1wt/R132H knock-in colorectal
cancer cells and HT1080 cells, a fibrosarcoma cell line
containing an endogenous IDH1R132C mutation. We per-
formed carbon tracing studies and investigated the ef-
fects of epigallocatechin-3-gallate (EGCG), an inhibitor
of GLUD1/2 and of NADP-dependent enzymes, on
D-2-HG synthesis and radiosensitivity of these cell lines.
Methods
Cell lines and compounds
HCT116-IH1wt/wt (parental) and HCT116-IDH1wt/R132H
knock-in human colorectal cell lines were generated by
AAV targeting technology GENESIS [31] and obtained
from Horizon Discovery (Cambridge, UK). HT1080
fibrosarcoma cells (containing an endogenous IDH1wt/
R132C mutation) were a kind gift of Dr. W. Hendriks
(Dept. of Cell Biology, Radboudumc). Cell lines were
cultured in DMEM (LONZA, Basel, Switzerland) supple-
mented with 10% FCS (Gibco, Waltham, MA) and
40 μg/μl gentamycin (Centrafarm, Etten-Leur, the
Netherlands). Cell lines were checked for IDH1R132H ex-
pression by Western blotting of cytosolic protein ex-
tracts, using a mutation-specific antibody (Dianova,
Hamburg, Germany; DIAH09). All experiments in this
study were performed with cells below passage number
25 as IDH1R132H expression levels gradually dropped at
higher passage numbers (data not shown). All chemicals
were obtained from Sigma Aldrich (St. Louis, MO) un-
less stated otherwise. EGCG (E4268) was stored in
DMSO at a concentration of 25 mM under nitrogen gas
and kept from light, or dissolved in distilled water dir-
ectly before use. The IDH1mut inhibitor AGI-5198 was
from MedChemExpress (Monmouth Junction, NJ).
13C-isotope tracing experiments
Nuclear magnetic resonance (NMR) spectroscopy and
LC-MS experiments were performed to investigate the
contribution of glutamine (Gln), glutamate (Glu), and
glucose (Glc) as carbon donors for D-2-HG (see Fig. 1a).
For NMR, HCT116-IDH1wt/R132H and HCT116 cells
were grown to 50% confluency in T175 culture flasks
(Greiner Bio-One, Kremsmünster, Austria) and incu-
bated with glutamine-free DMEM (Gibco) supplemented
with 10% FCS and 4mM [1-13C]-glutamine or 4 mM
[1-13C]-glutamate. EGCG (100 μM final concentration in
distilled H2O) or solvent control was administered 2 h
prior to the start of incubation. After 20 h of incubation,
cells were placed on ice, washed twice with ice-cold
PBS, and lysed in 2.5 ml methanol (MeOH) (− 20 °C)
containing 280 mM formic acid as a 1H and 13C (natur-
ally abundant) NMR reference compound. After 10
min, cell material was collected with a rubber police-
man, thoroughly vortexed and centrifuged for 5 min at
1200×g to precipitate proteins. The protein content of
the precipitated pellets was measured using a Pierce
BCA protein assay kit (ThermoScientific, Rockford, IL)
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and used for data normalization. The metabolites in the
supernatant were dried in a SpeedVac evaporator
(Savant, Waltham, MA) and redissolved in 400 μl D2O
for NMR analysis (Avance III 500MHz, Bruker BioS-
pin, Rheinstetten, Germany).
NMR spectra were acquired with pulse-acquire ex-
periments. For 1H NMR, the settings were TR = 18 s,
90° flip angle, NS = 16; and for 13C, TR = 5.1 s, 30° flip
angle, NS = 7000, and proton-decoupling. The spectra
were analyzed with Bruker Topspin software. Integrated
Fig. 1 Carbon sources for D-2-HG production and 13C tracing studies. a Schematic model of metabolic pathways involved in the production of
D-2-HG from extracellular glucose, glutamine, and glutamate; the 13C labeling patterns following incubation in culture medium containing 13C-
labeled glucose (light circles) and glutamine or glutamate (dark circles). b Example of 13C NMR spectra of extracts of HCT116-IDH1wt/R132H and
HCT116 cells cultured in medium with [1-13C]-glutamine (Gln*, blue) or [1-13C]-glutamate (Glu*, red). [1-13C]-D-2-HG (D-2-HG*) was detected at
181.8 ppm and could not be observed in parental HCT116 cells. c Quantified NMR results showing levels of Glu*, Gln*, and D-2-HG* in HCT116-
IDH1wt/R132H cells, after incubation in medium with Gln* (blue) or Glu* (red). d LC-MS analysis of D-2-HG pool fractional enrichments in HCT116-
IDH1wt/R132H cells after incubation with 13C-labeled substrates. Bar I displays the total amount of D-2-HG and the fractions that were derived from
Gln* (blue) and Glc* (gray). Results were obtained from two separate measurements: in the first measurement cells were incubated in DMEM with
Glc and Gln*; in the second measurement DMEM was supplemented with Glc* and Gln*. The difference in labeled fractions from these two
measurements was assigned as the Glc* fraction. In a parallel experiment Gln and Gln* were substituted by Glu and Glu* respectively. Bar II
shows the total amount of D-2-HG and the fractions that were derived from Glu* (red) and Glc* (gray). A third experiment was performed with
DMEM containing Glu*, Gln, and Glc. Bar III displays the total amount of D-2-HG and the fraction that was derived from Glu* (red). Provided that
both Glu and Gln are available from the culture medium, production of Glu-derived D-2-HG (red) was substantial. Gln* and Glc* fractions were
not measured in experiment III. Supplemented metabolite concentrations were always the same: 5.5 mM glucose and 4mM glutamine and/or
4 mM glutamate
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peak intensities of D-2-HG, Glu, and Gln were cor-
rected for T1 saturation, number of contributing spins,
and cell number and were referenced to formic acid to
obtain concentrations.
Because total amounts of D-2-HG are difficult to ob-
tain from 1H spectra, due to overlapping resonances of
D-2-HG and glutamate, total and 13C-labeled D-2-HG
pools were examined with LC-MS. To this end, HCT116
and HCT116-IDH1wt/R132H cells were grown to 50% con-
fluency in 10 cm culture dishes (Greiner Bio-One) and
incubated with Glc- and Gln-free DMEM with and with-
out 10% FCS and different combinations of non-labeled
and 13C-labeled Glc, Gln, or Glu. In all experiments, the
final total Glc concentration was 5.5 mM and Glu and/
or Gln concentrations were 4 mM. LC-MS was per-
formed as described before [32].
Proliferation assays
Cells were seeded in 96-well plates at 500 cells/well
(HCT116 cell lines) or 1000 cells/well (HT1080) and left
to adhere overnight. The following day varying concen-
trations of EGCG or vehicle were added. For AGI-5198
experiments, cells were cultured at least 3 days in the
presence of 5 μM AGI-5198, and the compound was left
on the cells during the entire experiment [21]. At days 2,
4, and 6 after seeding, total cell protein content was
measured using SRB assays, as described [33]. In short,
cells were washed twice with PBS and fixated overnight
at 4 °C in 10% (w/v) trichloroacetic acid. After fixation,
plates were washed four times with distilled H2O and
stored at − 20 °C until analysis. Plates were stained with
0.5% (w/v) SRB dissolved in 1% (v/v) acetic acid (Merck,
Darmstadt, Germany) and incubated in the dark for 20
min. After washing four times with 1% acetic acid, plates
were dried at 60 °C. Protein-bound SRB was solubilized
with 150 μl 10 mM Tris-HCl, pH 10. Optical densities
were measured at 560 nm on a microplate reader
(Bio-rad, Hercules, CA). Proliferation is expressed as
fold increase, normalized for the protein content of con-
trol cells 1 day after plating.
Alternatively, cell proliferation was measured using the
xCELLigence Real-Time Cell Analyzer system (ACEA
Biosciences, San Diego, CA). Cells were plated in dupli-
cate at a density of 1000 cells/well on ACEA E16 view
plates. The next day, EGCG or vehicle was added to the
wells. Doubling times were calculated over 48 h, using
dedicated ACEA software.
GLUD1/2 and IDH enzymatic assays
IDH1 was expressed as glutathione S-transferase (GST)-
fusion protein in pDEST15 and purified on glutathione
beads (GE Healthcare, Chicago, IL) as described [34].
Purified bovine GLUD1/2 was purchased from Serva
(Heidelberg, Germany). Enzyme reactions were initiated
by adding 4 μg IDH1 enzyme to a mixture of 100 μM
NADP+, 2 mM MgCl2, 0.5 mM isocitrate, and 100 mM
Tris-HCl (pH 7.4). GLUD1/2 activity was measured in
reactions containing 0.1 U bovine GLUD1/2 enzyme,
500 μM NAD+, 10 mM glutamate, and 2 mM ADP in
phosphate buffer (pH 8.0). Stoichiometric production of
NADPH and NADH was measured by real-time moni-
toring of NADPH or NADH absorbance at 340 nm with
20 s intervals on an Omega Fluostar (BMG Labtech,
Ortneberg, Germany).
Colony-forming assays after ionizing radiation (IR)
Cells, cultured with or without AGI-5198, were seeded
in 6-well plates (30–5000 cells/well) and left to adhere
overnight. Cells were treated with 0, 20, 50, or 100 μM
EGCG for 24 h and irradiated with 0, 2, or 4 Gy (IR, 3.1
Gy/min; XRAD 320 ix; Precision XRT; N. Brandford,
CT, USA). After 72 h, the medium was refreshed and
cells were cultured for another 7 days (without EGCG)
and fixated with 70% ethanol (10 min, 4 °C). After drying
at 60 °C, colonies were stained with 0.5% (w/v) crystal
violet (Merck) in distilled water. Colonies consisting of
50 cells or more were considered to be derived from
cells surviving radiotherapy and were manually counted.
The effect of EGCG on radiotherapy-induced cell death
was expressed as surviving fraction, normalized to plat-
ing efficiency.
DNA-double strand break (DSB) detection
Cells (cultured with or without AGI-5198) were plated
at a density of 300,000 cells/well in 6-well plates and left
to adhere overnight. After 24 h incubation with EGCG
(0, 50, or 100 μM), cells were irradiated with 0, 2, or 4
Gy. After 30 min, cytosolic extracts were prepared in 1×
RIPA buffer (Cell Signaling Technologies) containing 1
mM phenylmethylsulfonyl fluoride (PMSF). Cell extracts
were sonicated to release nuclear proteins. Protein sam-
ples (25 μg) were electrophoresed on 10% SDS-PAGE
gels and electroblotted onto nitrocellulose (GE Health-
care). Blots were stained with anti-γH2AX antibody
(Ser139; #2577; Cell Signaling Technologies) and
anti-γ-tubulin (C20) (Santa Cruz Biotechnology, Dallas,
TX, sc-7396), followed by appropriate secondary anti-
bodies labeled with IRDye680 or IRDye800 (Thermo-
Fisher). Signals were visualized and quantified using the
Odyssey system (Li-COR, Lincoln, NE).
Statistical analysis
Statistical analyses were performed in GraphPad Prism
v5.03 (GraphPad Software, LaJolla, CA). The difference in
mean values between various groups was assessed using an
unpaired Student’s t test, unless mentioned otherwise. P
values are marked as follows: < 0.05 (*); < 0.01 (**); < 0.001
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(***), < 0.0001 (****). Differences were considered statisti-
cally significant when P values were < 0.05.
Results
Glutamine and glutamate are carbon donors for D-2-HG
production
To find support for the hypothesis that glutaminolysis and/
or glutamatolysis is a rescue mechanism for IDHmut can-
cers, we used the HCT116 cell line and its isogenic
knock-in variant HCT116-IDH1wt/R132H. The balanced ex-
pression of both alleles makes this variant more representa-
tive for clinical cancers than overexpression models [35].
We used [1-13C]-labeled glutamine (Gln*) and glutamate
(Glu*) at similar concentrations to trace the routing of
carbons from Gln and Glu to D-2-HG. Labeled carbon
from Glu or Gln that enters the TCA cycle is lost as carbon
dioxide by oxidative decarboxylation of α-KG (see Fig. 1a).
13C-NMR spectra of extracts of IDH1mut cells, cul-
tured for 20 h in Gln*-containing DMEM, showed 13C
resonances for Glu and D-2-HG, demonstrating signifi-
cant carbon fluxes from Gln to Glu and to D-2-HG (see
blue graph in upper panel of Fig. 1b for a representative
NMR spectrum). In similar experiments with Glu* in-
stead of Gln* in the medium, we observed 13C reso-
nances for Gln and D-2-HG, next to that for Glu,
demonstrating carbon flux from Glu to Gln and to
D-2-HG (see red spectrum in the upper panel of Fig. 1b,
c). Whereas cells take up less Glu* than Gln*, the ratio
D-2-HG*/Glu* (0.36, n = 2) was higher than that of
D-2-HG*/Gln* in the Gln* incubation experiments (0.08,
n = 6; see Fig. 1c). Since D-2-HG was not detected in
parental HCT116 cells (see lower panel of Fig. 1b), these
cells were not used for further 13C experiments.
Relative contributions of Glu, Gln, and Glc carbons to
the total pool of D-2-HG were assessed with LC-MS of
extracts of cells, cultured 20 h in medium with Glu* or
Gln*, together with Glc* ([1,6-13C2]-glucose). Experi-
ments with Gln* + Glc* in the medium revealed that 64
± 8.5% of D-2-HG was derived from Gln* whereas 22 ±
3.8% was derived from Glc* (n = 5; see Fig. 1d, medium
formulation I). When cells were cultured in Glu* +
Glc*-containing DMEM in the absence of Gln, the total
amount of D-2-HG decreased, with 53 ± 3.1% of carbons
originating from Glu* and 31 ± 1.8% from Glc* (n = 3;
Fig. 1d, formulation II). Only small amounts of
non-labeled D-2-HG were detected when cells were cul-
tured in medium formulations I and II. When cultured
in DMEM with Glu* and non-labeled Gln and Glc, the
total amount of D-2-HG was highest (Fig. 1d, formula-
tion III). Of all intracellular D-2-HG, 41 ± 0.2% was de-
rived from Glu* (n = 3). The latter experiment showed
that direct glutamate contribution is substantial even in
the presence of glutamine and that the availability of
Gln is a prerequisite for increased D-2-HG production.
EGCG inhibits proliferation of IDHmut cells more
effectively than proliferation of IDHwt cells
Our finding that the glutamine-glutamate pathway is an
important carbon donor for D-2-HG via α-KG suggests
that blocking this pathway not only decreases α-KG
availability and D-2-HG production, but also increases
oxidative stress [21]. In line with this hypothesis, inhibit-
ing GLUD1/2 by EGCG dose-dependently reduced
growth rates of HCT116-IDH1wt/R132H cells more than
of parental HCT116 cells (Fig. 2a). Because the IDH1mut
inhibitor AGI-5198 prevents D-2-HG production and
NADPH oxidation [21], it is expected to annihilate the
metabolic stress that is caused by the IDH mutation,
thereby reducing the effects of EGCG. Indeed, AGI-5198
treatment antagonized the inhibitory effect of EGCG to
the level that was observed for parental HCT116 cells
(Fig. 2b). This finding was supported in experiments
with HT1080 cells, in which AGI-5198 treatment re-
sulted in significantly increased proliferation rates, while
decreasing sensitivity to EGCG (Fig. 2c).
EGCG inhibits GLUD1/2 and IDH1 activity
EGCG is an inhibitor of GLUD but also of other
NADP+-dependent enzymes [36], which could contrib-
ute to the reduction in growth rates of HCT116 and
HT1080 cells. We therefore tested the effects of EGCG
on enzymatic activities of wild-type IDH1 and GLUD1/2
in biochemical assays, quantifying NAD(P) H production
by 340 nm absorption. These experiments revealed
dose-dependent inhibition of both GLUD1/2 and of
IDH1 activity (Fig. 3).
EGCG reduces D-2-HG production in HCT116-IDH1wt/R132H
The effect of EGCG on IDH1 and GLUD1/2 activity pre-
dicts that EGCG inhibits the formation of α-KG and
D-2-HG in IDH1mut cells. To test this hypothesis, we an-
alyzed the effects of EGCG on D-2-HG production in
HCT116-IDH1wt/R132H cells using LC-MS. Total
amounts of D-2-HG were decreased in cells treated with
EGCG (Fig. 4a). This alteration was most apparent in
cells incubated in DMEM containing Glc, Glu, and Gln.
EGCG treatment decreased carbon flux from Glu* to
D-2-HG, although this difference was not statistically
significant (Fig. 4b). Because EGCG binds to serum albu-
min [37], possibly diminishing cellular uptake, we re-
peated the LC-MS experiment, but now cultured cells in
serum-free medium. Under these conditions, EGCG
treatment resulted in a significant reduction of 13C- flux
from *Glu to D-2-HG (Additional file 1: Figure S1).
EGCG increases sensitivity of HCT116-IDH1wt/R132H cells to
radiotherapy
Because EGCG inhibits GLUD1/2 and IDH1 activity and
thus NADH and NADPH production, it is expected to
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increase oxidative stress and sensitize cells for ionizing
radiation. Colony formation assays showed that EGCG
increased the sensitivity to IR of both cell lines, although
at low doses (20 μM) EGCG appeared to protect cells
against radiotherapy (Fig. 5a, Table 1). At higher doses
of EGCG, HCT116-IDH1wt/R132H cells were significantly
more sensitive to IR than HCT116 cells. Inhibition of
IDH1R132H activity with AGI-5198 resulted in decreased
radiosensitivity of EGCG-treated HCT116-IDH1wt/R132H
cells (dotted gray lines).
In addition to colony assays, we also measured γH2AX
to assess IR sensitivity. Phosphorylation of histone
H2AX is a rapid response to DNA-DSBs [38]. To test
the direct IR-induced DNA damage, we determined
levels of γH2AX in HCT116, HCT116-IDHwt/R132H, and
HT1080 cells with and without AGI-5198, 30 min after
irradiation with 0, 2, or 4 Gy. Endogenous levels of
γH2AX were higher in HCT116-IDH1wt/R132H than in
HCT116 cells (Fig. 5b) as reported before [21]. Higher
irradiation doses resulted in increased levels of γH2AX,
and there was a slight trend towards increased γH2AX
levels after EGCG treatment of HCT116-IDHwt/R132H,
but not HCT116, cells. A similar trend was observed in
HT1080 cells although differences did not reach statis-
tical significance (Fig. 5c). Of note, treatment with
AGI-5198 reduced the amount of γH2AX as was shown
before [21].
Discussion
Since the discovery of the frequent occurrence of IDH1
mutations in various types of cancer, research has mainly
focused on the oncogenic effects of D-2-HG, the
Fig. 2 Proliferation assays of the isogenic cell line pair HCT116 and HCT116-IDH1wt/R132H with EGCG. a Doubling times of cells as measured on the
xCELLigence. Doubling times for HCT116-IDH1wt/R132H (red bars) were significantly higher compared to its wild-type counterpart (blue bars).
Supplementation of EGCG to the culture medium increased doubling times in both cell lines, but this effect was more significant in HCT116-
IDH1wt/R132H. b SRB assay of HCT116 cells cultured with EGCG (dotted lines) or vehicle (solid lines). HCT116-IDH1wt/R132H (red lines) cells had slower
proliferation rates as compared to HCT116 (blue lines). Addition of AGI-5198 (gray lines) rescued the proliferation rates of IDH1R132H cells to
HCT116 baseline levels. EGCG inhibited proliferation of HCT116-IDH1wt/R132H more than HCT116, and this inhibitory effect was abolished by AGI-
5198. Similar results were obtained for HT10180 cells (c)
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product of the mutant enzyme [39]. Recognizing the
oncogenic role of D-2-HG, IDH1mut- and IDH2mut-spe-
cific drugs have been developed that inhibit the activity
of the mutant enzymes [19]. We recently showed that
these inhibitors not only inhibit the production of
D-2-HG, but also prevent NADPH oxidation [21]. This
results in normalization of the redox status of the cell
and thus decreased sensitivity to IR, which may imply
that these inhibitors are contra-indicated for combin-
ation treatment with IR. In glioma, mutations in IDH1
are considered ancestral, driving gliomagenesis but not
necessarily glioma progression [17]. In the initial stages
of neoplastic transformation, D-2-HG affects the epige-
nome through inhibition of α-KG-dependent DNA-and
histone-demethylases [40]. However, to overcome meta-
bolic stress induced by IDH mutations [41], during the
progression of the disease, IDHmut cells need to adopt
rescue mechanisms that supply the cells with the re-
quired basic level of α-KG to remain viable. The
existence of such rescue pathways could explain the
finding that α-KG levels are only slightly reduced in the
IDH1wt/R132H-mutant glioma model E478 [32], a finding
that was also made in other studies [13, 42]. Identifica-
tion of these pathways potentially allows the rational selec-
tion of metabolic inhibitors for therapeutic applications.
Previous in vitro and in vivo studies reported that
IDHmut cells rely on glutaminolysis for anaplerosis of
glutamate and production of reduced glutathione, an
important scavenger of reactive oxygen species [26, 29,
43, 44]. We recently postulated that metabolic rescue
mechanisms involve direct import and anaplerotic con-
sumption of glutamate and lactate in IDHmut, but not
IDHwt gliomas based on transcriptome and MR spec-
troscopy experiments [16, 25, 30]. Glutamate import is
regulated via excitatory amino acid transporters (EAAT)
which are expressed at high levels in IDHmut-glioma
cells [25] but at low levels in HCT116 cells [45]. In the
present work, we provide direct evidence using 13C-tra-
cing that glutamine and glutamate are carbon sources
for D-2-HG production, even in HCT116-IDH1mut cells.
In this study, we used in vitro glutamate concentrations
of 4 mM, which is higher than what is observed in
plasma in vivo and higher than in the extracellular space
in normal brain [46]. An open question is what the
levels of extracellular glutamate concentrations are in
brain tumors. As shown in Fig. 1, the presence of glu-
tamine in culture medium increased the intracellular
pool of D-2-HG in HCT116-IDH1wt/R132H cells. In
medium with *Glu in the absence of Gln, less D-2-HG
was produced but the contribution of *Glu-derived
carbon in D-2-HG was relatively high. We postulate
that the lower total D-2-HG pools are attributed to
lower uptake of glutamate relative to glutamine by
HCT116-IDH1wt/R132H cells.
Most research on IDHmut cancers is currently performed
on cell lines that overexpress IDH1mut [47, 48]. Recent evi-
dence suggests that the IDH mutation may be one of the
initial mutations that occur in glioma [49, 50]. Establishing
tumor models that carry the endogenous IDH1wt/R132H
mutation is difficult [51, 52], and overexpression models
are not necessarily representative for the heterozygous mu-
tation that occurs in these cancers [53]. Therefore, we here
used the heterozygous HCT116-IDH1wt/R132H knock-in cell
line, one of the few in vitro models carrying a heterozygous
IDH1wt/R132H mutation. The use of the isogenic cell line
pair (HCT116-IDH1wt/R132H and HCT116) allowed us to
link the IDH1 mutation to sensitivity to GLUD inhib-
ition. Our results may also have relevance to other
IDH1mut cancer types, as IDH mutations are also
found in colorectal cancers, although at low frequency
[17, 54]. Even though the importance of glutamate
and glutamine as an anaplerotic fuel might differ
Fig. 3 EGCG inhibits the activity of IDH1 and GLUD1/2. IDH1 (a) and GLUD1/2 (b) activities were inhibited by EGCG, but this effect was much
more pronounced in GLUD1/2. Activity was determined by measuring NADP(H)-generated absorption at 340 nm. Activity was corrected for
absorption measured with cofactors, without the addition of enzyme
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between cancer types due to the nature of cells, in-
hibition of the processing pathway downstream of
glutamine will hamper the cancer cells either way.
Previous studies have shown that the glutaminase
(GLS) inhibitor BPTES inhibits proliferation of
IDHmut cells [48]. The potential of cells to bypass
GLS activity by directly using glutamate instead of
glutamine is a possible explanation for the relatively
small inhibitory effect of BPTES in that study. There-
fore, inhibiting glutamatolysis at the level of GLUD1/
Fig. 4 LC-MS analysis of D-2-HG pools after treatment with EGCG. HCT116-IDH1wt/R132H cells were incubated in DMEM with 10% FCS,
supplemented with glucose, glutamine, and/or glutamate as indicated in the presence or absence of EGCG (shaded vs. non-shaded bars
respectively). a Total pools of D-2-HG after incubation in medium containing Glc and Gln (I), Glc and Glu (II), or Glc, Gln, and Glu (III). Total D-2-HG
levels decreased when cultured with EGCG. Fractional enrichments (FE) of D-2-HG are displayed in b. Blue bars display the fractions of D-2-HG
that were derived from Gln* (dark blue) and both Gln* and Glc* (light blue) after incubation in DMEM with Glc + Gln* (formulation Ia) and Glc* +
Gln* (formulation Ib) respectively. Red bars display the fractions of D-2-HG that were derived from Glu* (dark red) and both Glu* and Glc* (light
red) after incubation in DMEM with Glc + Glu* (formulation IIa) and Glc* + Glu* (formulation IIb) respectively, and the fraction of D-2-HG derived
from Glu* (dark red) after incubation in DMEM with Glc, Gln, and Glu* (formulation III)
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Fig. 5 EGCG increases radiosensitivity in HCT116-IDH1wt/R132H cells. a Colony formation assay of HCT116-IDH1wt/R132H cells shows increased
sensitivity to IR after treatment with EGCG compared to in HCT116. Surviving fractions were 5% (± 0.5%) vs. 16% (± 2%) for IDH1wt/R132H and
IDH1wt cells, respectively, when cultured with 100 μM EGCG and irradiated with 4Gy. b Western blot quantification of phosphorylated H2AX foci
in HCT116-IDH1wt/R132H and HCT116 cells, cultured with or without 100 μM EGCG and irradiated at 2 or 4 Gy. Endogenous H2AX-phosphorylation
was higher in HCT116-IDH1wt/R132H cells than in HCT116 cells. Thirty minutes after IR, γH2AX levels further increased to higher levels in HCT116-
IDH1wt/R132H than in HCT116 cells. The same trend could be observed in HT1080 (+ AGI-5198) cells (c)
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2 may be a more effective strategy. EGCG affects the
production of D-2-HG, among others, by diminishing
the supply of α-KG by inhibition of GLUD1/2 but
likely also by inhibition of the IDH1wt subunit, and
simultaneously deteriorates the redox status by inhi-
biting NAD(P) H production. In this way, EGCG has
clear benefits over inhibitors that only inhibit GLS or
mutant IDH activity directly. Glu-derived D-2-HG
production was inhibited more by EGCG than
Gln-derived D-2-HG. We explain this by the fact that
GLUD has both a mitochondrial and cytosolic iso-
form, while GLS is mitochondrial. As EGCG cannot
enter the mitochondrial matrix [55] Gln may lead to
the production of mitochondrial glutamate and α-KG
that may be processed in the TCA cycle instead of
being converted in the cytosol D-2-HG.
Cell growth was reduced by EGCG in both
HCT116 and HCT116-IDH1wt/R132H cell lines. We at-
tribute this to the fact that EGCG inhibits multiple
NADP+-dependent enzymes including IDH1wt [36].
We hypothesize that the significantly larger effect of
EGCG on HCT116-IDH1wt/R132H cells is caused by a
higher GLUD dependency compared to HCT116 cells.
However, it should be realized that EGCG is a pleio-
tropic compound, and activities other than GLUD
and IDH inhibition also may have played a role in
the observed effects.
A direct relationship between EGCG and increased
oxidative stress was established by its sensitizing
effect on radiotherapy, which was significantly higher
in HCT116-IDH1wt/R132H cells, as demonstrated by
decreased survival in colony forming assays and as
suggested by increased DNA-DSB after IR at high
doses of EGCG. Interestingly, a recent report de-
scribed that D-2-HG in IDH1mut cancers inhibits the
activity of the α-KG-dependent DNA repair enzyme
alkB homolog (ALKBH) [56]. This may provide an add-
itional explanation for increased baseline sensitivity of
IDH1mut cancers to radiation therapy and alkylating
chemotherapy. The decreased IR sensitivity of
HCT116-IDH1wt/R132H treated with AGI-5198 is in agree-
ment with this hypothesis.
EGCG has several other effects next to the inhibition
of GLUD. It can inhibit histone and DNA demethylases,
reactivate tumor suppressor genes [57–59], and inhibit
fatty acid synthase [60] and glucose-6-phosphate de-
hydrogenase, the rate-limiting enzyme in the pentose
phosphate pathway and a provider of NADPH [61].
Furthermore, EGCG has been reported to inhibit epider-
mal growth factor (EGF)-induced activation of the
EGF-receptor (EGFR) [62], a frequently encountered ab-
errant oncogenic pathway in glioblastoma and many
other cancers. The combination of these effects provides
a solid rationale to test EGCG as an adjuvant treatment
to radiotherapy, and possibly chemotherapy, also in
IDHwt cancers. However, our data also show that the
effects of EGCG may be dose-dependent, having a
radioprotective effect on HCT116-IDH1wt/R132H cells at
low doses. This may be due to both its anti-oxidative
and pro-oxidative effects [63] and warrants extra
investigation.
One problem that requires attention is the bioavail-
ability and stability of EGCG in vivo [55, 64, 65]. Anti-
cancer effects of EGCG can be diminished due to
oxidation of the compound [66], resulting in low
circulating doses after oral administration [67, 68].
Furthermore, EGCG in the circulation is mostly
albumin-associated, increasing stability but decreasing
bioavailability [37]. Methods to increase bioavailability
via nanomedicine and controlled delivery are currently
being explored [69, 70].
Conclusions
HCT116-IDH1wt/R132H cells use glutamine and glutam-
ate as direct sources for α-KG anaplerosis and D-2-HG
production. EGCG, a derivative of green tea, inhibits
glutamate processing at the level of GLUD1/2, reduces
proliferation rates, decreases production of D-2-HG, and
increases sensitivity to radiotherapy in IDH1wt/R132H
cells. Additional studies are required to test these con-
cepts in vivo and to investigate effective ways of deliver-
ing EGCG to the brain.
Table 1 Cell survival of irradiated cells. Surviving fractions are
presented as percentage surviving colonies (± standard deviation),
normalized to the non-irradiated control per EGCG treatment
condition. Colonies > 50 cells were considered to be derived from
cells that survived radiotherapy. Surviving fractions were
normalized to plating efficiency. The surviving fractions are also
visualized in Fig. 5a
EGCG (μM)
IR (Gy) 0 20 50 100
HCT116
0 100 (± 0) 100 (± 0) 100 (± 0) 100 (± 0)
2 74 (± 12) 62 (± 3) 48 (± 11) 50 (± 3)
4 44 (± 9) 37 (± 6) 19 (± 1) 16 (± 2)
HCT116-IDH1wt/R132H
0 100 (± 0) 100 (± 0) 100 (± 0) 100 (± 0)
2 33 (± 8) 50 (± 3) 39 (± 6) 16 (± 0.5)
4 24 (± 5) 28 (± 7) 5 (± 0.5) 5 (± 0.5)
HCT116-IDH1wt/R132H + AGI-5198
0 100 (± 0) 100 (± 0) 100 (± 0) 100 (± 0)
2 44 (± 11) 46 (± 9) 55 (± 3) 57 (± 17)
4 13 (± 4) 18 (± 2) 21 (± 2) 22 (± 6)
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Additional file
Additional file 1: Figure S1. LC-MS analysis of D-2-HG pools in cells
cultured in serum-free medium. HCT116-IDH1wt/R132H cells were incubated
in DMEM without FCS and with and without EGCG (shaded vs. non-
shaded bars respectively). Blue bars display the fractions of D-2-HG that
were derived from Gln* (dark blue) and both Gln* and Glc* (light blue)
after incubation in DMEM supplemented with Glc + Gln* (formulation Ia)
and Glc* + Gln* (formulation Ib) respectively. Red bars display the
fractions of D-2-HG that were derived from Glu* (dark red) and both Glu*
and Glc* (light red) after incubation in DMEM with Glc + Glu*
(formulation IIa) and Glc* + Glu* (formulation IIb) respectively, and the
fraction of D-2-HG that was derived from Glu* (dark red) after incubation
in DMEM with Glc, Gln and Glu* (formulation III). Fractional enrichments
of D-2-HG decreased significantly when incubated with EGCG. The
glucose fraction can be obtained by calculating the difference Ib-Ia and
IIb-IIa. Supplemented metabolite concentrations were always the
same: 5.5 mM glucose and 4 mM glutamine and/or 4 mM glutamate.
(TIF 1584 kb)
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